These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36115445)

  • 1. Does moderate hyperkalemia influence survival in HF? Insights from the MECKI score data base.
    Toto F; Salvioni E; Magrì D; Sciomer S; Piepoli M; Badagliacca R; Galotta A; Baracchini N; Paolillo S; Corrà U; Raimondo R; Lagioia R; Filardi PP; Iorio A; Senni M; Correale M; Cicoira M; Perna E; Metra M; Guazzi M; Limongelli G; Sinagra G; Parati G; Cattadori G; Bandera F; Bussotti M; Mapelli M; Cipriani M; Bonomi A; Cunha G; Re F; Vignati C; Garascia A; Lombardi C; Scardovi AB; Passantino A; Emdin M; Passino C; Santolamazza C; Girola D; Zaffalon D; Vizza D; De Martino F; Agostoni P;
    Int J Cardiol; 2023 Jan; 371():273-277. PubMed ID: 36115445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes in patients with cardiometabolic disease who develop hyperkalemia while treated with a renin-angiotensin-aldosterone system inhibitor.
    Johnson M; Morrison FJ; McMahon G; Su M; Turchin A
    Am Heart J; 2023 Apr; 258():49-59. PubMed ID: 36642227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: A systematic review.
    Fonseca C; Brito D; Branco P; Frazão JM; Silva-Cardoso J; Bettencourt P
    Rev Port Cardiol (Engl Ed); 2020 Sep; 39(9):517-541. PubMed ID: 32868174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.
    Linde C; Bakhai A; Furuland H; Evans M; McEwan P; Ayoubkhani D; Qin L
    J Am Heart Assoc; 2019 Nov; 8(22):e012655. PubMed ID: 31711387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.
    Butler J; Anker SD; Lund LH; Coats AJS; Filippatos G; Siddiqi TJ; Friede T; Fabien V; Kosiborod M; Metra M; Piña IL; Pinto F; Rossignol P; van der Meer P; Bahit C; Belohlavek J; Böhm M; Brugts JJ; Cleland JGF; Ezekowitz J; Bayes-Genis A; Gotsman I; Goudev A; Khintibidze I; Lindenfeld J; Mentz RJ; Merkely B; Montes EC; Mullens W; Nicolau JC; Parkhomenko A; Ponikowski P; Seferovic PM; Senni M; Shlyakhto E; Cohen-Solal A; Szecsödy P; Jensen K; Dorigotti F; Weir MR; Pitt B
    Eur Heart J; 2022 Nov; 43(41):4362-4373. PubMed ID: 35900838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
    Desai AS; Vardeny O; Claggett B; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Zile MR; Lefkowitz M; Shi V; Solomon SD
    JAMA Cardiol; 2017 Jan; 2(1):79-85. PubMed ID: 27842179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International validation of the Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) score in heart failure.
    Adamopoulos S; Miliopoulos D; Piotrowicz E; Snoek JA; Panagopoulou N; Nanas S; Niederseer D; Mazaheri R; Ma J; Chen Y; Popovic D; Seferovic P; Girola D; Corrà U; Coats AJS; Metra M; Rosano GMC; Volterrani M; Apostolo A; Campodonico J; Salvioni E; Agostoni P; Piepoli M
    Eur J Prev Cardiol; 2023 Sep; 30(13):1371-1379. PubMed ID: 37288595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of hyperkalemia and RAASi nonadherence on patients affected by heart failure or chronic kidney disease].
    Degli Esposti L; Perrone V; Giacomini E; Sangiorgi D; Alessandrini D; Santoro A
    G Ital Nefrol; 2019 Sep; 36(5):. PubMed ID: 31580544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
    Butler J; Anker SD; Siddiqi TJ; Coats AJS; Dorigotti F; Filippatos G; Friede T; Göhring UM; Kosiborod MN; Lund LH; Metra M; Moreno Quinn C; Piña IL; Pinto FJ; Rossignol P; Szecsödy P; Van Der Meer P; Weir M; Pitt B
    Eur J Heart Fail; 2022 Jan; 24(1):230-238. PubMed ID: 34800079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors.
    Kloner RA; Gross C; Yuan J; Conrad A; Pergola PE
    J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):524-531. PubMed ID: 30103622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study.
    Leon SJ; Whitlock R; Rigatto C; Komenda P; Bohm C; Sucha E; Bota SE; Tuna M; Collister D; Sood M; Tangri N
    Am J Kidney Dis; 2022 Aug; 80(2):164-173.e1. PubMed ID: 35085685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimally managing hyperkalemia in patients with cardiorenal syndrome.
    Wang AY
    Nephrol Dial Transplant; 2019 Dec; 34(Suppl 3):iii36-iii44. PubMed ID: 31800079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of RAASi-associated hyperkalemia in patients with cardiovascular disease.
    Silva-Cardoso J; Brito D; Frazão JM; Ferreira A; Bettencourt P; Branco P; Fonseca C
    Heart Fail Rev; 2021 Jul; 26(4):891-896. PubMed ID: 33599908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction.
    Savarese G; Xu H; Trevisan M; Dahlström U; Rossignol P; Pitt B; Lund LH; Carrero JJ
    JACC Heart Fail; 2019 Jan; 7(1):65-76. PubMed ID: 30553905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the Prognostic Performance of MECKI Score in Heart Failure Patients with Non-Valvular Atrial Fibrillation Treated with Edoxaban.
    Mapelli M; Mattavelli I; Salvioni E; Capra N; Bonomi A; Cattadori G; Pezzuto B; Campodonico J; Piotti A; Nava A; Piepoli M; Magrì D; Paolillo S; Corrà U; Raimondo R; Lagioia R; Vignati C; Badagliacca R; Perrone Filardi P; Senni M; Correale M; Cicoira M; Metra M; Guazzi M; Limongelli G; Parati G; De Martino F; Bandera F; Bussotti M; Re F; Lombardi CM; Scardovi AB; Sciomer S; Passantino A; Emdin M; Santolamazza C; Perna E; Passino C; Sinagra G; Agostoni P;
    J Clin Med; 2023 Dec; 13(1):. PubMed ID: 38202101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three Weeks of Inpatient Cardiac Rehabilitation Improves Metabolic Exercise Data Combined With Cardiac and Kidney Indexes Scores for Heart Failure With Reduced Ejection Fraction.
    Sakurai S; Murata M; Yanai S; Nitta S; Yamashita Y; Shitara T; Kazama H; Ueda M; Kobayashi Y; Namasu Y; Adachi H
    Circ Rep; 2023 Jun; 5(6):231-237. PubMed ID: 37305794
    [No Abstract]   [Full Text] [Related]  

  • 17. Association between hyperkalemia, RAASi non-adherence and outcomes in chronic kidney disease.
    Santoro A; Perrone V; Giacomini E; Sangiorgi D; Alessandrini D; Degli Esposti L
    J Nephrol; 2022 Mar; 35(2):463-472. PubMed ID: 34115311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
    Bakris GL; Pitt B; Weir MR; Freeman MW; Mayo MR; Garza D; Stasiv Y; Zawadzki R; Berman L; Bushinsky DA;
    JAMA; 2015 Jul; 314(2):151-61. PubMed ID: 26172895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life.
    Esteban-Fernández A; Ortiz Cortés C; López-Fernández S; Recio Mayoral A; Camacho Jurado FJ; Gómez Otero I; Molina M; Almenar Bonet L; López-Vilella R
    ESC Heart Fail; 2022 Oct; 9(5):3071-3078. PubMed ID: 35748119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry.
    Rossignol P; Lainscak M; Crespo-Leiro MG; Laroche C; Piepoli MF; Filippatos G; Rosano GMC; Savarese G; Anker SD; Seferovic PM; Ruschitzka F; Coats AJS; Mebazaa A; McDonagh T; Sahuquillo A; Penco M; Maggioni AP; Lund LH;
    Eur J Heart Fail; 2020 Aug; 22(8):1378-1389. PubMed ID: 32243669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.